Advertisement

Safety and efficacy of a topical treatment (SM04554) for androgenetic alopecia (AGA): Results from a phase 1 Trial

        Introduction: AGA, a form of hair loss impacting approximately 35 million men in the US, has received only two US drug approvals in the last 15 years. SM04554 is a novel small molecule, topical scalp treatment for AGA targeting the Wnt pathway, a pathway known to regulate hair growth. This abstract summarizes the analysis of a randomized, double-blind, placebo-controlled, single-center trial assessing safety and efficacy of SM04554 in treating AGA.
        To read this article in full you will need to make a payment
        AAD Member Login
        AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect